Isaac Sachmechi, MD
Endocrinology, Diabetes & Metabolism · New Hyde Park, NYNPI 1750340121
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $270,010 of the $349,092 with a category attached, or 77.3%. 60 manufacturers reported payments, led by Amgen at 24.7% of the total. Among endocrinology, diabetes & metabolism clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,301 payments — averaging $268.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$86K
- Abbott$63K
- Johnson & Johnson$41K
- Ascendis Pharma Endocrinology Inc$32K
- Intuity Medical Inc$26K
- Chiesi USA, Inc.$23K
- plus $80K from 54 others
Across 148 payments — averaging $3919.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$154K
- IBSA Institut Biochimique SA$107K
- Corcept Therapeutics$107K
- Astrazeneca UK Limited$106K
- Vertex$63K
- AbbVie$32K
- plus $12K from 3 others
What the payments were for
- Consulting fees$17,0785%
- Speaking & faculty fees$270,01077%
- Travel & lodging$26,0327%
- Food & beverage$35,65710%
- Education$3150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$77,557
- INVOKANA$39,651
- FREESTYLE LIBRE 3$33,419
- Yorvipath$31,223
- Pogo Automatic Blood Glucose Monitoring System$25,473
- MYCAPSSA$22,105
- FARXIGA$18,710
- NATPARA (PARATHYROID HORMONE)$14,836
- FreeStyle Libre$12,905
- FreeStyle Libre Pro$7,868
- FreeStyle Libre 2$7,510
- Korlym$5,854
- Prolia$5,480
- AFREZZA$4,380
- Roszet$3,978
- Tirosint$3,093
- STEGLATRO$2,744
- CYCLOSET$1,825
- Licart$1,102
- FLECTOR$1,102
How this compares
$349,092 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 190 | $367,156 |
| MounjaroTirzepatide | 87 | $195,800 |
| JardianceEmpagliflozin | 61 | $88,574 |
| FarxigaDapagliflozin Propanediol | 69 | $84,813 |
| ProliaDenosumab | 46 | $76,165 |
| JanuviaSitagliptin Phosphate | 61 | $51,663 |
| Tresiba Flextouch U-100Insulin Degludec | 74 | $49,998 |
| TradjentaLinagliptin | 34 | $45,763 |
| JanumetSitagliptin Phos/Metformin Hcl | 31 | $44,283 |
| TrulicityDulaglutide | 25 | $35,192 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $30,617 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $25,063 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 42 | $23,914 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $22,945 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $20,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,865 | $372,226207 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,756 | $230,992112 claims |
| Boehringer IngelheimJardiance, Tradjenta | $81 | $134,33695 claims |
| MerckJanuvia, Janumet, Janumet Xr | $8,111 | $118,891109 claims |
| AstraZenecaFarxiga | $20,495 | $84,81369 claims |
| AmgenProlia | $86,109 | $76,16546 claims |
| AbbVieSynthroid | $129 | $11,402143 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $781 | $5,147276 claims |
| PfizerPrempro | $431 | $2,56811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New Hyde Park
- Rory BreidbartNew Hyde Park$77K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.